Jørgen Frøkiær

Glucagon-like peptide-1: effect on pro-atrial natriuretic peptide in healthy males

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Standard

Glucagon-like peptide-1: effect on pro-atrial natriuretic peptide in healthy males. / Skov, Jeppe; Holst, Jens Juul; Goetze, Jens Peter; Frøkiær, Jørgen; Christiansen, Jens Sandahl.

In: Endocrine Connections, Vol. 3, No. 1, 10.12.2013, p. 11-16.

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Harvard

Skov, J, Holst, JJ, Goetze, JP, Frøkiær, J & Christiansen, JS 2013, 'Glucagon-like peptide-1: effect on pro-atrial natriuretic peptide in healthy males', Endocrine Connections, vol. 3, no. 1, pp. 11-16. https://doi.org/10.1530/EC-13-0087

APA

Skov, J., Holst, J. J., Goetze, J. P., Frøkiær, J., & Christiansen, J. S. (2013). Glucagon-like peptide-1: effect on pro-atrial natriuretic peptide in healthy males. Endocrine Connections, 3(1), 11-16. https://doi.org/10.1530/EC-13-0087

CBE

MLA

Vancouver

Author

Skov, Jeppe ; Holst, Jens Juul ; Goetze, Jens Peter ; Frøkiær, Jørgen ; Christiansen, Jens Sandahl. / Glucagon-like peptide-1: effect on pro-atrial natriuretic peptide in healthy males. In: Endocrine Connections. 2013 ; Vol. 3, No. 1. pp. 11-16.

Bibtex

@article{04b083eef8fb40ee9e985e1c48be8695,
title = "Glucagon-like peptide-1: effect on pro-atrial natriuretic peptide in healthy males",
abstract = "The antihypertensive actions of glucagon-like peptide-1 (GLP-1) receptor agonists have been linked to release of atrial natriuretic peptide (ANP) in mice. Whether a GLP-1 - ANP axis exists in humans is unknown. We examined twelve healthy young males in a randomised, controlled, double-blinded, single-day, cross-over study to evaluate the effects of a two-hour native GLP-1 infusion. Plasma proANP concentrations were measured by an automated mid-region-directed proANP immunoassay and N-terminal pro B-type natriuretic peptide (BNP) on Roche Modular E170. Urine was collected for measurements of sodium excretion. Although GLP-1 infusion increased the urinary sodium excretion markedly there were no significant changes in either proANP or proBNP concentrations. When GLP-1 infusion was stopped, sodium excretion rapidly declined. Since proANP concentration reflects ANP secretion our data cannot confirm the existence of a GLP-1 - ANP axis in humans. Especially the natriuretic effects of GLP-1 seem unlikely to be mediated exclusively via ANP.",
author = "Jeppe Skov and Holst, {Jens Juul} and Goetze, {Jens Peter} and J{\o}rgen Fr{\o}ki{\ae}r and Christiansen, {Jens Sandahl}",
year = "2013",
month = dec,
day = "10",
doi = "10.1530/EC-13-0087",
language = "English",
volume = "3",
pages = "11--16",
journal = "Endocrine Connections",
issn = "2049-3614",
publisher = "BioScientifica Ltd.",
number = "1",

}

RIS

TY - JOUR

T1 - Glucagon-like peptide-1: effect on pro-atrial natriuretic peptide in healthy males

AU - Skov, Jeppe

AU - Holst, Jens Juul

AU - Goetze, Jens Peter

AU - Frøkiær, Jørgen

AU - Christiansen, Jens Sandahl

PY - 2013/12/10

Y1 - 2013/12/10

N2 - The antihypertensive actions of glucagon-like peptide-1 (GLP-1) receptor agonists have been linked to release of atrial natriuretic peptide (ANP) in mice. Whether a GLP-1 - ANP axis exists in humans is unknown. We examined twelve healthy young males in a randomised, controlled, double-blinded, single-day, cross-over study to evaluate the effects of a two-hour native GLP-1 infusion. Plasma proANP concentrations were measured by an automated mid-region-directed proANP immunoassay and N-terminal pro B-type natriuretic peptide (BNP) on Roche Modular E170. Urine was collected for measurements of sodium excretion. Although GLP-1 infusion increased the urinary sodium excretion markedly there were no significant changes in either proANP or proBNP concentrations. When GLP-1 infusion was stopped, sodium excretion rapidly declined. Since proANP concentration reflects ANP secretion our data cannot confirm the existence of a GLP-1 - ANP axis in humans. Especially the natriuretic effects of GLP-1 seem unlikely to be mediated exclusively via ANP.

AB - The antihypertensive actions of glucagon-like peptide-1 (GLP-1) receptor agonists have been linked to release of atrial natriuretic peptide (ANP) in mice. Whether a GLP-1 - ANP axis exists in humans is unknown. We examined twelve healthy young males in a randomised, controlled, double-blinded, single-day, cross-over study to evaluate the effects of a two-hour native GLP-1 infusion. Plasma proANP concentrations were measured by an automated mid-region-directed proANP immunoassay and N-terminal pro B-type natriuretic peptide (BNP) on Roche Modular E170. Urine was collected for measurements of sodium excretion. Although GLP-1 infusion increased the urinary sodium excretion markedly there were no significant changes in either proANP or proBNP concentrations. When GLP-1 infusion was stopped, sodium excretion rapidly declined. Since proANP concentration reflects ANP secretion our data cannot confirm the existence of a GLP-1 - ANP axis in humans. Especially the natriuretic effects of GLP-1 seem unlikely to be mediated exclusively via ANP.

U2 - 10.1530/EC-13-0087

DO - 10.1530/EC-13-0087

M3 - Journal article

C2 - 24327600

VL - 3

SP - 11

EP - 16

JO - Endocrine Connections

JF - Endocrine Connections

SN - 2049-3614

IS - 1

ER -